• Aged 21 and above
• Ability to provide informed consent
• 42 normal controls: No diabetes and free from clinically relevant eye disease that interferes with the aim of the study i.e. glaucoma, diabetic retinopathy, age-related macular degeneration, uveitis, or vascular occlusive diseases
• 76 subjects with pathological myopia (up to -12 dioptres) or staphyloma

• Aged 10 to 18
• 23 subjects with low to moderate myopia (-0.75 to -6 dioptres)
• 23 subjects with high myopia (more than -6 dioptres)
• Ability of legal representative and subject to provide informed consent

The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.

High reproducibility in myopia cases as shown in PS-OCT derived sclera anisotropy patterns

Changes in scleral anisotropy in adults with different degrees of myopia (up to -12 dioptres), as associated with the presence of staphyloma

Anisotropy correlation with refraction and axial length in children with low (-0.75 to -6 dioptres) and high (more than -6 dioptres) myopia, as measured by PS-OCT